These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23343250)

  • 21. The cost-effectiveness of screening for oral cancer in primary care.
    Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F
    Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness and cost-utility of long-term management strategies for heartburn.
    Goeree R; O'Brien BJ; Blackhouse G; Marshall J; Briggs A; Lad R
    Value Health; 2002; 5(4):312-28. PubMed ID: 12102694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating essential hypertension. The first choice is usually a thiazide diuretic.
    Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
    Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN
    BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms.
    Hogendoorn W; Lavida A; Hunink MG; Moll FL; Geroulakos G; Muhs BE; Sumpio BE
    J Vasc Surg; 2015 Jun; 61(6):1432-40. PubMed ID: 25827968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information.
    Campbell JD; McQueen RB; Libby AM; Spackman DE; Carlson JJ; Briggs A
    Med Decis Making; 2015 Jul; 35(5):596-607. PubMed ID: 25349188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
    Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
    Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Probabilistic cost-effectiveness analysis of the treatment of sleep apnea].
    Mar J; Gutiérrez-Moreno S; Chilcott J
    Gac Sanit; 2006; 20(1):47-53. PubMed ID: 16539993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of information analysis for a new technology: computer-assisted total knee replacement.
    Dong H; Coyle D; Buxton M
    Int J Technol Assess Health Care; 2007; 23(3):337-42. PubMed ID: 17579936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
    Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
    Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness and value of information analysis of nutritional support for preventing pressure ulcers in high-risk patients: implement now, research later.
    Tuffaha HW; Roberts S; Chaboyer W; Gordon LG; Scuffham PA
    Appl Health Econ Health Policy; 2015 Apr; 13(2):167-79. PubMed ID: 25650349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.